Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone

With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade.

On June 30, Wedbush analyst Laura Chico raised the firm's price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $43 from $32 while maintaining an Outperform rating following the company's investor call after the approval of Lumvoa. Management confirmed that Lumvoa will be priced at $450,000 per treatment course, broadly in line with the cost of Tepezza. Wedbush believes the pricing strategy should face limited resistance from payers and noted that Lumvoa's label includes both active and chronic thyroid eye disease (TED) patients, providing the company with a strong commercial foundation and a competitive advantage as it enters the market.

Also on June 30, Truist increased its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $38 from $35 while reiterating a Buy rating. The firm highlighted Lumvoa's differentiated profile, including a more convenient dosing schedule than the current market leader while maintaining pricing parity. Truist also pointed to management's commercialization strategy, which targets rapid adoption in a significantly underpenetrated TED market, with meaningful revenue expected by 2027. In addition, the company plans to expand the franchise through a subcutaneous formulation, with a biologics license application anticipated during the first quarter of 2027.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biopharmaceutical company headquartered in Waltham, Massachusetts, and was originally founded in 2007. The company focuses on discovering, developing, and commercializing innovative therapies for rare and serious autoimmune diseases, with an emphasis on thyroid eye disease and other underserved conditions requiring targeted biologic treatments.

While we acknowledge the potential of VRDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Fusion Energy Development Stocks to Buy and 7 Best Battery Technology Stocks to Buy for Grid Storage.

Disclosure: None. Follow Insider Monkey on Google News.